Pfizer Corporation

Other

Ball Corporation

Juventas Therapeutics, Inc.

Evonik Degussa Gmbh

The Cleveland Clinic Foundation

Hydra Unlimited, LLC

Vaxliant, LLC

Air Products and Chemicals, Inc.

Evonik Operations Gmbh

Huvepharma, Inc.

Timothy J Miller

Elaine V Jones

Edward C Miller

Albert Paul Reed

Sharon R Klepfer

Joseph M Pastore

Jean Louise Vincent

Marc S Penn

Mary Ann Pfannenstiel

Rahul Aras

Juan Jesus Burdeniuc

Ganesh Madhusudan Sathe

Michael Thomas Clark

Hector Wasunna Alila

Shawn Patrick O'Brien

Renee Jo Keller

Mark W Herrema

Brian T Suiter

Robert A Clare

Thomas A DeRossett, Jr

Nancy E Pfeiffer

Patricia Lufburrow

James Douglas Tobias

Mark William Mellencamp

Gary Dale Andrew

Kai Xi

Jared Denis Bender

Robert Hoffman

Jane Garrett Kniss

Goran Zarkov

Tadao Yasue

Irene Joann Hsu

Robert Francis Hoffman

Renée Jo Keller

Growing media

A synthetic growing media, such as for a hydroponic growing system, includes a plastic body having multiple legs pointing in different directions. One or more of the legs has a bulbous tip. A synthetic growing medium comprising an aggregate of synthetic growing media and hydroponic system for plant cultivation are also disclosed.

The present disclosure provides for an adjuvant composition that is suited for injectable as well as transdermal administration. The adjuvant composition generally comprises a lipophile, a polymer of acrylic or methacrylic acid, saline, cholesterol, a saponin, and sodium hydroxide. A vaccine composition is also provided for that generally includes the vaccine composition of the present disclosure and an antigen. A method for vaccinating animals and humans utilizing the adjuvant composition of the present disclosure is also provided.

Adjuvant compositions and related methods

A catalyst composition for making polyurethane foam, the catalyst composition including a compound having a general formula RRRN, wherein each of R, Rand Rare independently selected from the group consisting of: wherein n=1 to 5; and R4, R5 and R6 are each independently hydrogen, methyl, ethyl and propyl groups; hydrogen, a C1-C6 alkyl group compound, a C1-C6 cycloalkyl group compound, a C1-C6 alkenyl group compound, a C1-C6 alkynyl group compound, a C1-C6 aryl group compound, and a C1-C6 aralkyl group compound, each group being substituted or unsubstituted; wherein at least one of R, Rand Ris a compound according to formula (I). A polyurethane composition and method for forming a polyurethane foam are also disclosed.

Amine composition useful for making polyurethane foam

The present disclosure provides for an adjuvant composition that is suited for injectable as well as transdermal administration. The adjuvant composition generally comprises a lipophile, a polymer of acrylic or methacrylic acid, saline, cholesterol, a saponin, and sodium hydroxide. A vaccine composition is also provided for that generally includes the vaccine composition of the present disclosure and a DNA component. A method for vaccinating animals and humans utilizing the adjuvant composition of the present disclosure is also provided.

Catalyst compositions useful in the production of insulating polyurethane or polyisocyanurate foam are disclosed. The catalyst compositions impart increased stability of a mixture of the catalyst, a halogen-containing blowing agent, and a polyol. These catalyst compositions comprise of at least 10% of a tetraalkylguanidine and at least 10% of a tertiary amine catalyst with an isocyanate reactive group. These improved catalysts can be used with any halogenated blowing agent, and provide substantial stability benefits with the use of hydrofluoroolefins and hydrofluorochloroolefins. In an exemplary embodiment, a process includes providing a pre-mix comprising a hydrohaloolefin blowing agent, at least one polyol, water, and a catalyst comprising 10-50% tetramethylguanidine and 10-90% of one or more of an amine catalyst containing an isocyanate reactive group.

Amine catalyst for improving the stability of polyurethane systems having halogen containing blowing agents

A composition and process to make polyisocyanurate or polyurethane foam using a catalyst composition comprising at least one bismuth carboxylate catalyst and one or more co-catalysts selected from the group of alkali metal carboxylates and quaternary ammonium carboxylate salts, such that the resultant foam has improved insulation properties. The polyisocyanurate or polyurethane foams produced by this catalyst composition and method are useful for laminated boardstock, construction panels, appliance insulation, and spray-applied insulation.

Catalyst compositions and methods for making foam

Catalyst compositions useful in the production of insulating polyurethane or polyisocyanurate foam are disclosed. The catalyst compositions impart increased stability of a mixture of the catalyst, a halogen-containing blowing agent, and a polyol. These catalyst compositions include amine/acid salts with a pH of &#x3c;7.0 which can be used in combined with tertiary amine catalysts and metal-based or ammonium-based trimerization catalyst and at least one metal-based gel catalyst and optionally one or more of an additional catalyst described in (1) or (2). These improved catalysts can be used with any halogenated blowing agent, and provide substantial stability benefits with the use of hydrofluoroolefins and hydrofluorochloroolefins. In an exemplary embodiment, a process includes providing a pre-mix comprising an organic carboxylic di-acid, tri-acid or poly-acid component and contacting a tetraalkylguanidine and/or a tertiary amine containing an isocyanate reactive group with the acid component in the pre-mix to form a mixture of tetraalkylguanidine salt or tertiary amine salt or their combination.

Delay action catalyst for improving the stability of polyurethane systems having halogen containing blowing agents

A method of treating a cardiomyopathy in a subject includes administering directly to or expressing locally in a weakened, ischemic, and/or peri-infarct region of myocardial tissue of the subject an amount of SDF-1 effective to cause functional improvement in at least one of the following parameters: left ventricular volume, left ventricular area, left ventricular dimension, cardiac function, 6-minute walk test, or New York Heart Association (NYHA) functional classification.

SDF-1 delivery for treating ischemic tissue

Alkylethoxylate alcohols or mixtures of alkyl alcohol ethoxylate with an average HLB value between 10 and 15 as compatibilizers for water blown polyurethane foam formulations that are substantially free of nonylphenol ethoxylates are disclosed. The HLB is defined as the mass percent of average structure of the compatibilizer that is hydrophilic, divided by 5. The compatibilizer is mixed into the B-side of the polyurethane formulation. The B-side of the spray foam formulations comprise polyol, water, amine catalyst, and the compatibilizer of the invention such that the water is present at about 2% to about 30% by weight of the B-side formulation, and the compatibilizer is present at about 1% to about 30% by weight of the B-side formulation. The B-side of the formulation may further comprise metal catalysts, flame retardants, silicone surfactants, cell openers, antioxidants, as well as other additives.

NPE-free emulsifiers for water-blown polyurethane spray foam

Provided herein are methods of treating a cardiomyopathy in a subject by administering directly to, or expressing locally in, a weakened, ischemic, and/or peri-infarct region of myocardial tissue of the subject an amount of SDF-1 effective to cause functional improvement in at least one of the following parameters: left ventricular volume, left ventricular area, left ventricular dimension, cardiac function, 6-minute walk test, or New York Heart Association (NYHA) functional classification. Also provided are methods of treating critical limb ischemia in a subject by administering a DNA plasmid encoding human SDF-1 by direct injection into the affected limb.

A system, method, and device for etching an indicia onto a substrate includes a compact laser etching device having a delivery head, an emitter housing, a RF cable, and a communication cable. The delivery head has a beam steering mechanism and a hood assembly positioned between the beam steering mechanism and the substrate. The emitter housing has a laser for generating a laser beam, and a fold mirror positioned in an optical path of the laser beam for redirecting the laser beam into the beam steering mechanism. A remote RF electronics package drives the laser. Control electronics cause the beam steering mechanism to steer the laser beam into a pattern of the indicia. The delivery head may further include a plurality of suction cups for holding the compact laser etching device in engagement with the substrate.

Compact laser etching device, system and method

A system, method, and device for etching an indicia onto a piece of glass or other inorganic oxide includes a compact laser etching device having a delivery head, an emitter housing, a RF cable, and a communication cable. The delivery head has a beam steering mechanism and a hood assembly positioned between the beam steering mechanism and the piece of glass. The emitter housing has a laser for generating a laser beam, and a fold mirror positioned in an optical path of the laser beam for redirecting the laser beam into the beam steering mechanism. A remote RF electronics package drives the laser. Control electronics cause the beam steering mechanism to steer the laser beam into a pattern of the indicia. The delivery head may further include a plurality of suction cups for holding the compact laser etching device in engagement with the piece of glass.

Growing community of inventors

Lincoln, NE, United States of America

Timothy J Miller